

Pharmacoeconomic Unit Report 2013-2015

<u>NO</u>	<u>Intervention</u>	<u>Trade Name</u>	<u>Comparator</u>	<u>Sent From</u>	<u>indication</u>	<u>Released Date</u>	<u>Recomm endation</u>	<u>Presented At</u>
<u>1</u>	Drug eluting stent	STENT	Bare metal stent	Minister of technical office	Diabetic patients	4/2013	<u>Cost effective</u>	<u>ISPOR16th annual European congress Dublin, Ireland</u>
<u>2</u>	Sapropterin Dihydrochloride	KUVAN	Phenylalanine Free Diet	Technical Office For Head Of CAPA	Phenyl ketone urea	9/8/2013	<u>Risk Sharing Agreement</u>	<u>ISPOR16th annual European congress Dublin, Ireland</u>
<u>3</u>	Insulin	INSULIN 100 Unit	Insulin 40 Unit	Drug Shortage Department	Diabetes mellitus	16/4/2014	<u>Cost saving</u>	<u>ISPOR 6th Asia pacific conference Beijing, China</u>
<u>4</u>	Pazopanib	VOTRIENT	Sunitinib	Tenders Office	Metastatic renal cell carcinoma	15/1/2014	<u>Cost saving</u>	<u>ISPOR 19th annual international meeting Montreal, Canada</u>

<u>5</u>	Everolimus	AFFINITOR	Gemcitabine+paclitaxel / Capecitabine+docetaxil	Tenders Office	Metastatic Breast Cancer Patients	2/2/2014	<u>Small budget impact</u>	<u>ISPOR17th annual European congress Amsterdam, The Netherlands</u>
<u>6</u>	Lapatinib	TYKERB	CAPECITABINE	Tenders Office	HER-2–Positive Metastatic Breast Cancer	29/5/2014	<u>Not cost effective</u>	<u>ISPOR17th annual European congress Amsterdam, The Netherlands</u>
<u>7</u>	Zoledronic Acid	ACLASTA	Alendronate	Tenders Office	Treatment of Osteoporosis in post- menopausal women.	16/7/2014	<u>Cost effective</u>	<u>ISPOR 18th Annual European Congress November 9th - 11th 2014, Milan, Italy</u>
<u>8</u>	Aprepitant	EMEND	Dexamethazone+ Ondosterone	Tenders Office	as add-on therapy to the standard regimen in patients receiving highly emetogenic therapy	25/6/2014	<u>Cost effective</u>	<u>ISPOR17th annual European congress Amsterdam, The Netherlands</u>

<u>9</u>	Bortezomib	VELCADE	Vincristine+ Adriamycin Dexamethasone	Tenders Office	previously untreated Multiple Myeloma patients	28/5/2014	<u>Risk sharing agreement</u>	<u>Not published yet</u>
<u>10</u>	Lenalidomide	REVLIMIDE	Dexamethazone	Pricing committee	Multiple Myeloma patients	16/7/2014	<u>Risk Sharing Agreement</u>	<u>Not published yet</u>
<u>11</u>	Trastuzumab emtansine	kadcyla	Lapatinib+capecitab ine	biological products Registration	HER-2-Positive Advanced Breast Cancer	29/10/2014	<u>Risk sharing agreement s</u>	<u>Not published yet</u>
<u>12</u>	lidocaine+tetra caine	litraglis	lidocaine+prolicaine	pricing committee	Topical Anaesthesia Before Vascular Access	26/10/2014	<u>No added value compared to EMLA</u>	<u>ISPOR 18th Annual European Congress November 9th - 11th 2014, Milan, Italy</u>
<u>13</u>	Ethyl ester of iodic oleic acid	lipiodol ultra fluid	drug eluting beads	Drug Shortage department	Treatment Of Hepato-cellular Carcinoma	27/10/2014	<u>Cost effective</u>	<u>Not published yet</u>

<u>14</u>	Ipilimumab	Yervoy	Best supportive care	Biological department	unresectable or metastatic melanoma	18/02/2015	<u>Risk sharing agreements</u>	<u>Not published yet</u>
<u>15</u>	Fidaxomicin	clostridax	vancomycin	pricing	Clostridium difficile Infection	18/8/2014	<u>Cost effective</u>	<u>Not published yet</u>
<u>16</u>	paclitaxel	Taxol	docetaxel	Oncology institution	Early operable breast cancer	19/3/2015	<u>Cost effective</u>	<u>Not published yet</u>
<u>17</u>	Insulin degludec	tresiba	Insulin glargine	Biological department	Type 1&2 diabetes mellitus	19/3/2015	<u>Not cost effective</u>	<u>Not published yet</u>
<u>18</u>	Insulin degludec / insulin aspart	ryzodeg	Humalog mix 25, 50mg	Biological department	Type 1&2 diabetes mellitus	19/3/2015	<u>Not cost effective</u>	<u>Not published yet</u>
<u>19</u>	imiglucerase	cerezyme	Best supportive care	Minister of health	Gaucher disease	30/3/2015	<u>Very high budget impact</u>	<u>Not published yet</u>

<u>20</u>	Darbepoetin alfa	aranesp	Epoetin alfa	Health care sectors	maintaining hemoglobin target level in hemodialysis patients	12/10/2015	<u>Cost effective</u>	<u>Not published yet</u>
<u>21</u>	Agalsidase beta	fabrazyme	Best supportive care	Health care sectors	Fabry disease	28/10/2015	<u>Highly not cost effective</u>	<u>Not published yet</u>
<u>22</u>	Adalimumab, tocilizumab	Humira, actemra	infliximab	Health care sectors	moderate to severe rheumatoid arthritis in Egypt	28/10/2015	<u>Adalimumab is the highly cost effective>infliximab>tocilizumab</u>	<u>Not published yet</u>
<u>23</u>	Zoledronic acid	zometa	Pamidronic acid	Oncology institution	Breast cancer with bone metastasis	4/11/2015	<u>Cost effective</u>	<u>Not published yet</u>